Medtronic CEO Geoff Martha discusses innovations such as pulse field ablation, renal denervation, DBS, TAVR, diabetes tech ...

Medtronic says CMS is opening a national coverage analysis on renal denervation (RDN) procedures for patients with ...

Medicare may begin to cover renal denervation with Medtronic’s Symplicity device by October, which could drive coverage among ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

Medtronic had to overcome a major supplier glitch in its latest quarter as it tried to keep pace with other large medical-technology companies racing to commercialize new catheter technology that ...

Medtronic is picking up steam with recent product launches, and its balance sheet is a fortress. Read more about MDT stock ...

The global peripheral angioplasty market, valued at USD 3.4 billion in 2023, is projected to more than double, reaching USD 7 ...

The interventional cardiology landscape is shifting rapidly, led by advanced balloon catheters, bioabsorbable stents, and ...

New technologies for atrial fibrillation, hypertension, diabetes and neurological conditions are poised for fast growth, Martha said Monday at the J.P. Morgan Healthcare Conference.

NYSE:MDT) Medtronic announces CMS national coverage analysis for Symplicity(TM) Spyral Renal Denervation System ...